Pulmonary
Pulmonary Regenerative Medicine
Physician-directed stem cell and exosome protocols for COPD, pulmonary fibrosis, and long COVID respiratory conditions.
Chronic respiratory conditions can severely limit quality of life and respond incompletely to conventional medications. Our pulmonary regenerative program uses Wharton's jelly-derived mesenchymal stem cells (MSCs) and exosome therapy to target lung inflammation, support tissue repair, and improve functional capacity. Every patient is evaluated by a pulmonary specialist before protocol selection to ensure safety and suitability.
What patients experience
- May reduce airway inflammation and support lung tissue repair
- Targeted protocols for COPD, pulmonary fibrosis, and long COVID
- Intravenous infusion plus optional nebulized exosome delivery
- Comprehensive respiratory function assessment and follow-up
- Personalized medical nutrition and rehabilitation coordination
- 97% cell viability with GMP-certified laboratory production
Treatment protocol
Treatment typically begins with a full pulmonary evaluation including spirometry, six-minute walk test, chest imaging review, and inflammatory markers. Based on results, patients receive an IV MSC infusion and/or nebulized exosome therapy. The program is integrated with respiratory physiotherapy and medical nutrition to maximize outcomes. Follow-up is conducted at 1, 3, and 6 months to track pulmonary function, symptom scores, and quality-of-life metrics.
Free consultation
Talk to our medical team about your case
Get a personalized treatment plan and transparent pricing within 24 hours.